Skip to content

Author

P. Suryawanshi

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Systemic Explanation of Alpinia officinarum’s Analyzed Compounds and Its Anti-Cancer Mechanism Based on In Vitro Analysis and Network Pharmacology in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer lacking ER, PR, and HER2 expression, often associated with poor prognosis, early relapse, and resistance to conventional chemotherapy. Due to the limited availability of targeted therapies, natural products have gained attention for their st...

S. Sinnarkar, P. Suryawanshi, A. Jadhav et al. · 0 citations
Sep 2026

Diabetic serum preconditioning augments human umbilical cord mesenchymal stem cell secretome therapeutic efficacy in reversing insulin resistance in 3T3-L1 adipocytes.

BACKGROUND Insulin resistance, metabolic dysfunction, inflammation, and vascular impairment characterize Type 2 Diabetes Mellitus (T2DM). Mesenchymal stem cells (MSCs) have shown promise in preclinical studies. However, their variable efficacy in human settings warrants strategies to enhance their therapeutic potency....

N. Mante, V. Undale, Avinash Sanap et al. · 0 citations
Review Sep 2026

Emerging Biomarkers Across the Clinical Spectrum of SARS-CoV-2 Infection and Long COVID

Long COVID, also referred to in the literature as postacute sequelae of SARS-CoV-2 infection (PASC) or postacute COVID-19 syndrome (PACS), is a chronic and heterogeneous multisystem condition persisting beyond acute COVID-19. For consistency, this review uses the term “Long COVID” throughout; PASC and PACS are noted on...

Akhilesh Koli, Ayush Khangar, Sharmilla Khatri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.